Moreover, DMC–CHC combined with cisplatin greatly suppresses cisplatin resistance protein ERCC1 and TP through the PI3K-AKT pathway, permitting increased cisplatin-induced NSCLC apoptosis [129]. Here, AKT1 is linked to non-small cell lung carcinoma.